Dr. Osamu Ishiba]shi received his M.S. from Tokyo Institute of Technology (Japan) in 1993. In the same year, he joined a pharmaceutical company, Ciba-Geigy Japan (currently Novartis Pharma), and conducted basic research leading to the development of novel antiosteoporosis drugs, including cathepsin K inhibitors. Based on the achievements in the company, he received his Ph.D from Nagaoka University of Technology (Japan) in 2000. He then accepted academic positions including a postdoctoral fellow with the Max-Planck Institute of Biochemistry (Germany) and as a senior scientist in Niigata University (Japan). In 2006, he joined Nippon Medical School as a senior assistant professor and started new projects focused on the microRNA-mediated regulation of cell functions. In 2012, he accepted his current position (associate professor) with Osaka Prefecture University (Osaka Metropolitan University since 2022) to conduct studies on genome-wide transcriptomics associated with pathology including cancer and kidney diseases. Dr. Ishibashi has published more than 60 publications in international peer-review journals. He also serves as an editorial board member or associate editor for a number of journals.